Rifampin induced hepatotoxicity during treatment for chronic central serous chorioretinopathy.
OBJECTIVE
The purpose of this report is to present a case of hepatotoxicity secondary to off-label rifampin therapy for the treatment of chronic central serous choroidopathy.


METHODS
Case report.


RESULTS
A patient with chronic central serous chorioretinopathy was treated with oral rifampin. Three weeks after the initiation of therapy, fatigue, nausea, and malaise associated with elevated liver enzyme elevations were noted. Symptoms resolved and liver enzymes normalized after discontinuing rifampin.


CONCLUSIONS
Rifampin-induced hepatic injury can occur during therapy for chronic central serous chorioretinopathy. Potential hepatotoxicity must be considered and followed closely during off-label rifampin treatment.
*Des Moines University, Des Moines, Iowa; and †Wolfe Eye Clinic, West Des Moines, Iowa.
Joel
J
Nelson
David D
DD
Saggau
Jared S
JS
Nielsen
D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D002908:Chronic Disease; D006801:Humans; D008297:Male; D019384:Nucleic Acid Synthesis Inhibitors / Q000009:adverse effects*; D012293:Rifampin / Q000009:adverse effects*
D019384:Nucleic Acid Synthesis Inhibitors; D012293:Rifampin